Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23342020 | 0.91 | CHRNB2 (0.37) | MEN1KMT2ASMN1; SMN2CHRNB2CHRNA3 | |
| SCHEMBL25895223 | 0.90 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2CHRNB2CHRNA3 | |
| SCHEMBL23342149 | 0.89 | HPGD (0.36) | MEN1KMT2ASMN1; SMN2CHRNB2CHRNA3 | |
| SCHEMBL25912481 | 0.87 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2CHRNB2CHRNA3 | |
| SCHEMBL25895224 | 0.86 | CHRNB2 (0.47) | MEN1KMT2ASMN1; SMN2CHRNB2CHRNA3 | |
| SCHEMBL25041235 | 0.85 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL25900443 | 0.80 | PDE4B (0.37) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL20063342 | 0.78 | PKM (0.38) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL20063362 | 0.78 | PKM (0.38) | MEN1KMT2ASMN1; SMN2HSD17B10GAA | |
| SCHEMBL12233572 | 0.78 | XPNPEP2 (0.45) | MEN1KMT2ACHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024116207-A1 | ADAR1 INHIBITORS AND METHODS OF USING THE SAME | AVAMMUNE THERAPEUTICS INC. (IN) | 2024-06-06 | — | — | WO | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | MEN1 340/4885KMT2A 3873/4885SMN1; SMN2 3861/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | MEN1 2520/4885KMT2A 3021/4885SMN1; SMN2 1139/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 815/4885KMT2A 3685/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.